[Form 4] BIOMARIN PHARMACEUTICAL INC Insider Trading Activity

Rhea-AI Filing Summary

BioMarin Pharmaceutical insider Gregory R. Friberg, listed as Executive Vice President and Chief R&D Officer, reported a sale of 3,304 shares of BioMarin common stock on 09/30/2025 at a price of $54.16 per share. After the transaction, the reporting person beneficially owned 43,506 shares. The Form 4 was signed on 10/02/2025 by an attorney-in-fact.

Positive

• None.

Negative

• Insider sale of 3,304 shares reported on 09/30/2025

Insights

Corporate Governance Analyst

Insider sale disclosed: 3,304 shares sold at $54.16.

The filing documents an open-market sale by an officer, reducing reported holdings to 43,506 shares. This is a routine Form 4 disclosure required under Section 16 and simply reports a completed transaction.

Because the filing contains only the sale details and ending beneficial ownership, it does not disclose planned future transactions, reasons for the sale, or any company-sensitive information.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Friberg Gregory R

(Last) (First) (Middle)

C/O BIOMARIN PHARMACEUTICAL INC.

770 LINDARO STREET

(Street)

SAN RAFAEL CA 94901

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIOMARIN PHARMACEUTICAL INC [ BMRN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief R&D Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/30/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/30/2025		F		3,304	D	$54.16	43,506	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

	/s/ Tae Sang Yoo, Attorney-in-Fact	10/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the BioMarin (BMRN) Form 4 filed by Gregory R. Friberg disclose?

The Form 4 shows a sale of 3,304 shares on 09/30/2025 at $54.16 per share, leaving 43,506 shares beneficially owned.

What is Gregory R. Friberg's role at BioMarin (BMRN)?

He is reported as an Executive Vice President, Chief R&D Officer in the Form 4.

When was the Form 4 signed for the BioMarin insider transaction?

The Form 4 was signed by an attorney-in-fact on 10/02/2025.

Does the Form 4 disclose why the insider sold shares?

No. The Form 4 lists the transaction details but does not provide a reason for the sale.

How many shares did the reporting person own after the transaction?

The reporting person beneficially owned 43,506 shares after the reported sale.